Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
A new study suggests sildenafil, known by its brand name Viagra, can improve cerebrovascular function and minimize the risk of cognitive impairment caused by small vessel disease.
Paul Zei, MD, discusses late-breaking data from the REAL-AF Registry, which looked at the short- and long-term outcomes of radiofrequency ablation in paroxysmal and persistent atrial fibrillation.
Researchers developed an advanced AI model capable of extracting measurements from unprocessed CT images in seconds. It then uses those data to evaluate the patient's mortality risk if they underwent TAVR.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
